94594-91-9

Usage

Uses

Used in Pharmaceutical Industry:
Oppolzer's camphor sulfam is used as a chiral reagent for the production of Pharmaceuticals, facilitating chiral transformations with high enantioselectivity, which is crucial for the development of new drugs and other biologically active molecules.
Used in Agrochemical Industry:
Oppolzer's camphor sulfam is used as a chiral reagent in the production of agrochemicals, enabling the synthesis of bioactive compounds and pharmaceutical intermediates with high enantioselectivity, which is essential for the development of effective and safe agrochemical products.
Used in Organic Synthesis:
Oppolzer's camphor sulfam is used as a building block in the synthesis of bioactive compounds and pharmaceutical intermediates, playing a critical role in the advancement of medicinal and chemical research. Its exceptional properties and versatility make it an effective reagent in the field of organic synthesis.

Upstream product

• 814-68-6 acryloyl chloride 
• 94594-90-8 (2R)-bornane-10,2-sultam 
• 2051-76-5 acrylic acid anhydride 
• 21286-54-4 (+)-(1S)-Campher-10-sulfonsaeure-chlorid 
• 60886-80-8 (+/-)-8,8-dimethyl-4,5,6,7-tetrahydro-3ar,6c-methano-benz[c]isothiazole-2,2-dioxide 
• 167934-73-8 N-trimethylsilylbornane-10,2-sultam 
• 119897-86-8 N-<(4,5-dihydro-3-ethyl-(5R)-5-isoxazolyl)carbonyl>-(2R)-bornane-10,2-sultam 
• 119897-85-7 N-<(4,5-dihydro-3-methyl-(5R)-5-isoxazolyl)carbonyl>-(2R)-bornane-10,2-sultam 
• 60886-80-8 (1S)-(-)-camphorsulfonylimine 
• 60933-63-3 (1S)-10-camphorsulfonamide 
• 21286-54-4 Camphorsulfonyl chloride 
• 3144-16-9 (1S)-10-camphorsulfonic acid 
• 17854-63-6 (+/-)-2-oxo-bornane-10-sulfonic acid amide 
• 167872-57-3 3-benzyloxy-2-bromopropanoyl bromide 

Downstream Products

• 109053-73-8 (3aS,6R,7aR)-8,8-dimethyl-1-[(2E)-3-phenylprop-2-enoyl]hexahydro-3a,6-methano-2,1-benzisothiazole 2,2-dioxide 
• 158195-43-8 acetic acid (6S)-(10,10-dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]decane-4-carbonyl)-(1R)-cyclohex-2-enyl ester 
• 133706-01-1 ((1S,5R,7R)-10,10-Dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]dec-4-yl)-(3-phenyl-2-trimethylsilanyloxy-isoxazolidin-5-yl)-methanone 
• 127381-61-7 <3aS<1<1R^*,5R^*,6R^*>,3aα,6α,7aβ>>-Hexahydro-8,8-dimethyl-1-<<8-methyl-2,4-dioxo-3-(phenylmethyl)-3,8-diazabicyclo<3.2.1>oct-6-yl>carbonyl>-3H-3a,6-methano-2,1-benzisothiazole 2,2-dioxide 
• 127470-56-8 <3aS<1<1S^*,5R^*,6R^*>,3aα,6α,7aβ>>-Hexahydro-8,8-dimethyl-1-<<8-methyl-2,4-dioxo-3-(phenylmethyl)-3,8-diazabicyclo<3.2.1>oct-6-yl>carbonyl>-3H-3a,6-methano-2,1-benzisothiazole 2,2-dioxide 
• 127381-62-8 [(1S,5R,6S)-6-((1S,5R,7R)-10,10-Dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]decane-4-carbonyl)-8-methyl-2,4-dioxo-3,8-diaza-bicyclo[3.2.1]oct-3-yl]-phenyl-acetic acid methyl ester 
• 127381-62-8 <3aS<1<1S^*,3(R^*,S^*),5R^*,6R^*>,3aα,6α,7aβ>>-8-Methyl-2,4-dioxo-α-phenyl-6-<(tetrahydro-8,8-dimethyl-3H-3a,6-methano-2,1-benzisothiazol-1(4H)-yl)carbonyl>-3,8-diazabicyclo<3.2.1>octane 3-acetic acid methyl ester S,S-dioxide 
• 127381-63-9 Acetic acid (S)-2-[(1S,5R,6S)-6-((1S,5R,7R)-10,10-dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]decane-4-carbonyl)-8-methyl-2,4-dioxo-3,8-diaza-bicyclo[3.2.1]oct-3-yl]-2-phenyl-ethyl ester 
• 127381-63-9 <3aS<1<1S^*,3(R^*),5R^*,6R^*>,3aα,6α,7aβ>>-1-<<3-<2-(Acetyloxy)-1-phenylethyl>-8-methyl-2,4-dioxo-3,8-diazabicyclo<3.2.1>oct-6-yl>carbonyl>hexahydro-8,8-dimethyl-3H-3a,6-methano-2,1-benzisothiazole 2,2-dioxide 
• 127381-65-1 <3aS<1<1S^*,3(R^*),5R^*,6R^*>,3aα,6α,7aβ>>-1-<<3-<2-<<(1,1-Dimwthylethyl)dimethylsilyl>oxy>-1-phenylethyl>-8-methyl-2,4-dioxo-3,8-diazabicyclo<3.2.1>oct-6-yl>carbonyl>hexahydro-8,8-dimethyl-3H-3a,6-methano-2,1-benzisothiazole 2,2-dioxide 
• 145625-20-3 3-<(1S)-N-(tert-butyloxycarbonyl)amino-2-phenylethyl>-5-<(2R)-(bornane-10,2-sultamyl)-N-carbonyl>-(5R)-Δ²-isoxazoline 
• 145679-60-3 {(S)-1-[(S)-5-((1S,5R,7R)-10,10-Dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]decane-4-carbonyl)-4,5-dihydro-isoxazol-3-yl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 145625-16-7 3-<(4R)-3-carboxybenzoxy-2,2-dimethyl-4-oxazolidinyl>-5-<(2R)-(bornane-10,2-sultamyl)-N-carbonyl>-(5R)-Δ²-isoxazoline 
• 20681-51-0 methyl 3-cyclohexylpropionate 

Relevant academic research and scientific papers

ASYMMETRISCHE INDUKTION BEI DER NI(0)-KATALYSIERTEN -CYCLOADDITION VON CAMPHERSULTAMACRYLAT MIT METHYLENCYCLOPROPANEN

The asymmetric Ni(0)-catalyzed cycloaddition of (-)-camphorsultamacrylate with methylenecyclopropane or 2,2-dimethylmethylenecyclopropane leads to 3-methylenecyclopentanecarboxylic amides in high optical yields up to 98percent de.

Conjugate of cytotoxin molecule and cell binding receptor molecule

A conjugate of a strong cytotoxin molecule and a cell binding receptor molecule has a structure shown in a molecular formula (I), wherein T, L, m, n, -----, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are defined in the text. The conjugate is used for treating cancer, immunological diseases and infectious diseases.

CONJUGATE OF CELL-BINDING RECEPTOR WITH CYTOTOXIC AGENT

PROBLEM TO BE SOLVED: To provide a conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule for targeted treatment. SOLUTION: According to the present invention, there is provided a conjugate having a structure of formula (I) and a pharmaceutical acceptable salt and a solvate thereof. The conjugate is used for treating cancer, autoimmune disease, and infectious disease. (T is a targeting or binding ligand; L is a releasable linker; a broken line is a linkage bond that L connects to a molecule inside the bracket independently; n is an integer of 1 to 20; m is an integer of 1 to 10; and a structure in parentheses is a potent antimitotic agent/drug.) SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Diastereoselective ru-catalyzed cross-metathesis-dihydroxylation sequence. An efficient approach toward enantiomerically enriched syn-diols

(Chemical Equation Presented) Sequential catalysis has evolved as a powerful concept within the past years and allows the more efficient use of catalytically active expensive transition metals in organic synthesis. In this paper we present the stereoselective cross-metathesis-dihydroxylation of various olefins with chiral auxiliary substituted acrylamides. The chiral information (i.e., the auxiliary) introduced in the metathesis reactions allows for a stereoselective subsequent RuO4-catalyzed dihydroxylation. The sequence is concluded by an unusual kinetic resolution of the diastereomeric diols obtained in the oxidation reaction. As a consequence a variety of structurally diverse enantiomerically enriched diols are obtained. To the best of our knowledge the results summarized in this paper represent the first highly efficient diastereoselective RuO4-catalyzed oxidation.

Synthetic routes to a constrained ring analog of didemnin B

The didemnin class of biologically active cyclodepsipeptides, isolated from a marine tunicate, has shown antitumor, antiviral, and immunosuppressive activities. Synthetic studies were undertaken to prepare a modified analog of one of the most potent congeners, didemnin B (1). The side chain of the isostatine unit was tethered into the macrocycle via a cyclohexane ring in order to provide a more rigid conformation and determine the importance of this unit in bioactive compounds. This modification created a new macrocycle core and generated a diastereomeric mixture of a constrained analog of didemnin B (2).

Diastereoselective Synthesis of α-Bromo amides leading to Diastereomerically Enriched α-Amino-, α-Hydroxy- and α-Thiocarboxylic Acid Derivatives

α-Bromo amides derived from Oppolzer's camphorsultam can be prepared diastereoselectively starting from racemic α-bromo acids, and undergo epimerisation under appriopriate conditions leading to an enhanced d.e..By reacting the individual isomers or the mi

Stereoselectivity and Generality of the Palladium-Catalysed Cyclopropanation of α,β-Unsaturated Carboxylic Acids Derivatized with Oppolzer's Sultam

A series of α,β-unsaturated carboxylic acids derivatized with camphorsultam 1 a s a chiral auxiliary has been stereoselectively cyclopropanated. the selectivity of the reaction produces cyclopropanated products with the 1R,2R absolute configuration as indicated by the optical rotations as well as by an X-ray structure determineation.The temperature dependence of the reaction was studied with three substrates. the highest stereoselectivity was obtained at temperatures above 25 deg C.Branching at the α- or β-carbons disfavours complete conversion, and electron-withdrawing substituents at these positions seem to prevent the reaction.The auxiliary was removed by using titanium(IV) isopropoxide in benzyl alcohol followed by alkaline hydrolysis of the intermediate ester. the potent 5-HT1A receptor agonist (1R,2S)-2-(2-hydroxyphenyl)-N,N-dipropylcyclopropylamine 13 was synthesized by this method

Synthetic studies of a constrained ring didemnin analog

An asymmetric Diels-Alder reaction in the presence of 3.0 M lithium perchlorate-diethyl ether was used to generate the initial stereochemistry for a cyclohexane amino acid (3), a key intermediate in the preparation of a fused ring didemnin analog. This constrained ring macrocycle should provide insight into the binding site conformation of the bioactive species.

Asymmetric silyl nitronate cycloadditions with bornane-10,2-sultam derivatives

Asymmetric silyl nitronate cycloadditions with N-acryloyl (2R)-bornane-10,2-sultam, N-acryloyl (2S)-bornane-10,2-sultam, and N-methacryloyl (2R)-bornane-10,2-sultam have been studied. The asymmetric silyl nitronate cycloaddition/elimination methodology pr